Pitolisant
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Pitolisant: From Narcolepsy to Insomnia
One-Sentence Summary
Pitolisant is a histamine H3 receptor inverse agonist originally developed and internationally approved for excessive daytime sleepiness in narcolepsy (with or without cataplexy) and residual sleepiness in OSA — it is not currently marketed in this jurisdiction. The TxGNN model predicts it may be effective for Insomnia, but this prediction is mechanistically counter-intuitive (a wake-promoting drug for a sleep-inducing indication) and is supported only by 1 withdrawn, zero-enrollment trial and 8 publications, none of which directly studied insomnia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy with/without cataplexy, excessive daytime sleepiness in OSA (per international literature; no local registration data exists) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L4 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed official mechanism of action data is not available (flagged as a High-severity data gap). Based on the literature collected in this evidence pack, pitolisant is a selective histamine H3 receptor inverse agonist/antagonist. By blocking H3 autoreceptors, it increases histamine, norepinephrine, and acetylcholine release in the brain, producing a wake-promoting effect. This mechanism underlies its approved use for excessive daytime sleepiness in narcolepsy and its investigational use for residual sleepiness in CPAP-treated OSA patients.
This mechanistic direction runs counter to the proposed new indication. A drug designed to increase wakefulness is pharmacologically more likely to induce or worsen insomnia than to treat it — indeed, insomnia is a known adverse effect of H3 receptor antagonism in clinical use. The single registered trial in this evidence pack (NCT02800083) was not actually an insomnia trial; it targeted alcohol use disorder, was withdrawn, and enrolled zero patients, so it provides no usable signal for sleep-related endpoints. None of the 8 supporting publications studied pitolisant for insomnia — they cover narcolepsy pharmacology, OSA-related daytime sleepiness, and general H3 receptor biology.
The TxGNN score most likely reflects a semantic proximity between "sleep disorder" concepts in the model's embedding space (narcolepsy, OSA, insomnia are all sleep-related nodes) rather than a genuine therapeutic relationship. This prediction should be treated as a candidate requiring mechanistic reassessment, not a validated repurposing lead.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02800083 | Phase 2 | Withdrawn | 0 | Designed to evaluate pitolisant for alcohol use disorder (reduction in heavy drinking days), with secondary endpoints touching on mental health/sleep improvement. Trial was withdrawn with zero enrollment, so no efficacy or safety data were generated. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36931805 | 2023 | RCT | The Lancet. Neurology | Phase 3 trial confirming safety/efficacy of pitolisant in pediatric narcolepsy with/without cataplexy — not an insomnia study. |
| 33121980 | 2021 | RCT | Chest | Pitolisant reduced residual excessive daytime sleepiness in CPAP-adherent OSA patients — a wake-promoting effect, opposite direction to insomnia treatment. |
| 31917607 | 2020 | RCT | Am J Respir Crit Care Med | Pitolisant improved daytime sleepiness in OSA patients refusing CPAP — again a wake-promoting outcome. |
| 36169322 | 2022 | Cohort | Revista de neurología | Real-world "WAKE study" on pitolisant effectiveness/safety in treatment-refractory type 1 narcolepsy. |
| 34225942 | 2021 | Review | Handbook of Clinical Neurology | General review of brain histamine receptors (H1–H4) in health and disease; no insomnia-specific data. |
| 30214155 | 2018 | Review | Drug Design, Development and Therapy | Review of pitolisant's development and therapeutic role in narcolepsy. |
| 34521328 | 2022 | Review | Current Neuropharmacology | Reviews histaminergic system changes in neuropsychiatric disorders; notes pitolisant is used for narcolepsy sleepiness, contrasted with H1-antagonist doxepin used for insomnia. |
| 22356925 | 2012 | Review | Clinical Neuropharmacology | Early report on pitolisant as a stimulant alternative for refractory sleepiness in narcolepsy-cataplexy. |
None of the eight publications evaluate pitolisant as a treatment for insomnia; several explicitly document its wake-promoting profile.
Other Predicted Indications (Lower Priority, Not Detailed Above)
- ADHD (score 99.36%, Evidence Level L5): Plausible mechanistic rationale via H3-receptor-mediated cortical arousal/cognition pathways, but zero registered clinical trials and 7 supporting papers are all general H3-receptor pharmacology reviews with no direct ADHD trial data. Recommendation: Hold.
- Faciodigitogenital syndrome (Aarskog-Scott syndrome) (score 99.29%, Evidence Level L5): No identifiable biological link — this is an FGD1 gene mutation-driven X-linked developmental disorder unrelated to histamine H3 signaling. Zero trials, zero literature. Assessed as likely model noise from sparse rare-disease ontology embeddings. Recommendation: Hold.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (insomnia) is mechanistically implausible given pitolisant's wake-promoting pharmacology, and its only associated trial was withdrawn with zero enrollment. The two lower-ranked predictions (ADHD, faciodigitogenital syndrome) have even weaker evidentiary support (L5 — model prediction only, no clinical or, in the case of faciodigitogenital syndrome, mechanistic support). None of the three candidates meet the bar to advance past S0.
To proceed, the following is needed:
- TFDA/local package insert warnings and contraindications (currently a Blocking data gap — cannot complete S1 safety screening without it)
- Confirmed DrugBank mechanism of action record (currently a High-severity data gap)
- If insomnia remains of interest, a mechanistic explanation for how an H3 inverse agonist could treat rather than induce insomnia, ideally with new preclinical or clinical data, before further evaluation
- DDI dataset (current query returned no results) before any safety assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.